Ionis Pharmaceuticals 주식 (NASDAQ: IONS)

에 대한 최신 뉴스 Ionis Pharmaceuticals (NASDAQ:IONS) 주식

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 8.46% on an annualized basis producing an average annual return of 21.53%. Currently, Fluor has a market capitalization of $8.59 billion. 
Buying $1000 In FLR: If an investor had bought $1000 of FLR stock 5 years ago, it would be worth $2,708.87 today based on a price of $50.06 for FLR at the time of writing.
<h3>Fluor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735336808_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Fluor Stock In The Last 5 Years

The NFL aired two games on Christmas Day in 2024, a move that may have angered the NBA while also bringing in <a href="https://www.benzinga.com/media/24/12/42701434/netflixs-nfl-debut-brings-record-streams-but-lags-traditional-tv-report">impressive viewership figures.</a>
What Happened: While many sports leagues see strong viewership in the United States, the NFL has been king for years and that may have been even more evident with streaming records set Wednesday for its <a href="https://www.benzinga.com/24/12/42695495/netflix-nfl-games-show-super-bowl-contenders-mvp-frontrunner-poll-27-watch">premiere on streaming giant</a> Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
Two NFL Christmas Day games featuring four teams who have made the NFL Playoffs broke records for the league with an average of 24.1 million viewers for the earlier Kansas City Chiefs at Pittsburgh Steelers game and an average of 24.3 million viewers for the Baltimore Ravens at Houston Texans game.
The <a href="https://about.netflix.com/en/news/netflix-nfl-christmas-gameday-reaches-65-million-us-viewers">ratings </a>beat a previous NFL streaming record of 23 million set by Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with an exclusive game on Peacock during the previous NFL Playoffs. The figures also broke a regular-season record of 17.92 million set by the Detroit Lions and Green Bay Packers on Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) owned Prime Video in December, as reported by <a href="https://frontofficesports.com/nfl-netflix-debut-sets-streaming-records-as-nba-sees-84-increase/">FrontOfficeSports</a>.
Netflix said Nielsen data showed 65 million U.S. viewers watched at least one minute of the NFL games, with average viewership peaking at 27 million during Beyoncé&#8217;s halftime performance in the Ravens and Texans game.
NBA superstar LeBron James might not want to see the viewership figures and hear about the records.
After the Los Angeles Lakers defeated the Golden State Warriors on Christmas Day, James declared the holiday as belonging to the NBA.
"I love the NFL. I love the NFL. But Christmas is our day," James said.
Read Also: <a href="https://www.benzinga.com/24/12/42689806/netflix-to-release-beyonce-bowl-nfl-halftime-performance-as-standalone-special">Netflix To Release &#8216;Beyoncé Bowl&#8217; NFL Halftime Performance As Standalone Special</a>
Can NBA and NFL Both Win?: While Christmas produced records for the NFL, the NBA also enjoyed a strong day for viewership.
The NBA aired five games on Christmas Day, which aired on ABC, ESPN, ESPN+ and Disney+, all units of The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).
NBA Christmas Day games averaged 5.25 million viewers, up 84% year-over-year. Helping the viewership may have been the teams involved and the fact that all five games were available on ABC, while only two were last year.
This figure is the highest for the NBA on the holiday in five years. The Lakers and Warriors game averaged 7.76 million viewers, ranking as the NBA's most-watched Christmas Day game since 2019.
For the 2024 NBA season, viewership is now down 4% year-over-year after the Christmas day games, compared to being down 18% year-over-year ahead of Wednesday.
NBA viewership on ESPN platforms is now up 4% year-over-year, as reported by <a href="https://deadline.com/2024/12/nba-christmas-day-ratings-lakers-warriors-1236242578/">Deadline</a>.
The NBA could also benefit from the Christmas Day games, with its owned NBA League Pass reporting its most-viewed Christmas Day ever.
What's Next: For the NFL, encroaching on other sports isn't exactly new and likely won't be changing anytime soon.
The NFL began Monday Night Football games in 1970 and later added Thursday Night Football games in 2006, which now stream on Prime Video.
NFL games air on Saturdays during December and January, diverging from the league&#8217;s usual avoidance of the day for most of the season due to NCAA Football and the restrictions of the 1961 Sports Broadcasting Act. This year, the NCAA expanded its College Football Playoffs from four to 12 teams, leading to a rare head-to-head clash with the NFL last weekend.
On Saturday, Dec. 21, the NFL had two games, and there were three College Football Playoffs games, with two airing on TNT Sports, a unit of Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), and one airing on ABC and ESPN.
Netflix has a three-year deal with the NFL and will stream at least one game on Christmas for the next two seasons.
The increase in Christmas Day games from the NFL might come as a bit of a surprise after the league said last year it was only scheduling games on Christmas 2023 because the day fell on Monday, a traditional NFL date, as <a href="https://www.nbcsports.com/nfl/profootballtalk/rumor-mill/news/lebron-james-i-love-the-nfl-but-christmas-is-the-nbas-day">reported </a>by NBC Sports.
The league said it wouldn't schedule games on Christmas if it fell on a Tuesday or Wednesday previously, according to the report, but strong viewership last year and the potential for more money may have changed the league's mind.
Netflix has more sports content coming with its WWE deal through a partnership with TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), premiering on Jan. 6.
The NBA is likely stuck with going head-to-head with the NFL on Christmas Day, regardless of what day the holiday falls on. One way for the NBA to get back at the NFL would be to start <a href="https://www.benzinga.com/general/sports/24/11/42226470/heres-why-the-detroit-lions-dallas-cowboys-always-have-thanksgiving-day-nfl-games">scheduling games on Thanksgiving</a>, a date the league has avoided due to the NFL having three games that day.
NFLX Price Action: Netflix stock was down 1.8% to $907.55 on Friday, versus a 52-week trading range of $461.86 to $941.75.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42702484/if-you-invested-1000-in-netflix-stock-when-squid-game-was-released-heres-how-much-youd-have-today">If You Invested $1,000 In Netflix Stock When &#8216;Squid Game&#8217; Was Released, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Shutterstock

Entertainment

Sports

AMZN

CMCSA

NFLX

LeBron James Vs. NFL: NBA Star Declares Christmas 'Our Day,' But 2024 Ratings Disagree

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 20.91% on an annualized basis producing an average annual return of 33.99%. Currently, Murphy USA has a market capitalization of $10.23 billion. 
Buying $1000 In MUSA: If an investor had bought $1000 of MUSA stock 5 years ago, it would be worth $4,297.27 today based on a price of $505.23 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735335907_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

Here's How Much $1000 Invested In Murphy USA 5 Years Ago Would Be Worth Today

National Security Council spokesman John Kirby said Friday there are "early indications" that Russian air defenses may have been involved in the Azerbaijan Airlines crash on Christmas Day, <a href="https://www.benzinga.com/news/global/24/12/42686735/azerbaijan-airliner-crash-kills-38-weather-russia-under-scrutiny">killing 38 and injuring 29.</a>
The Washington Post <a href="https://www.washingtonpost.com/world/2024/12/27/azerbaijan-airlines-plane-crash-russia/">reports</a> Kirby emphasized these findings are preliminary, as investigations into the crash remain ongoing.
What Happened: The flight, en route from Baku to Grozny, diverted midflight before ultimately crashing in Kazakhstan. Kirby highlighted that the evidence extends beyond images of the damaged aircraft, though he declined to provide further details, according to WaPo.
Azerbaijani officials have also cited "external interference" as the likely cause, with initial investigations showing the wreckage bore marks consistent with an air-defense missile.
Passengers and crew reported hearing three explosions near Grozny, with cutting debris injuring those onboard. Azerbaijani Minister of Digital Development and Transport Rashad Nabiyev confirmed that the injuries were caused by objects piercing the fuselage, The Post reports.
Azerbaijani Airlines has since suspended flights to multiple Russian cities, citing ongoing safety concerns.
Also Read: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42707484/exxonmobil-stock-navigates-death-cross-market-signals-turn-bearish-for-the-oil-giant">ExxonMobil Stock Navigates Death Cross: Market Signals Turn Bearish For Oil Giant</a>
Why It Matters: The suggestion of Russian involvement has amplified geopolitical tensions in a region already fraught with conflict. If confirmed, the incident would deepen mistrust between Azerbaijan and Moscow, raising broader questions about the safety of air travel in conflict zones.
The U.S. has offered to assist Azerbaijani and Kazakh officials in the investigation, underscoring the international significance of the findings.
Russian authorities initially blamed weather conditions and bird strikes but later mentioned drone activity near Grozny, which had triggered radar jamming. But survivors described an external impact according to The Post. &#8220;We felt a blow from outside,&#8221; a flight attendant said, noting the plane broke apart on impact.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42710358/veteran-investor-bets-big-on-sp-500-hitting-7000-by-end-of-2025-these-sectors-could-lead-the-charge">Veteran Investor Bets Big On S&amp;P 500 Hitting 7,000 By End Of 2025: These Sectors Could Lead The Charge</a></li>
</ul>
Photo: EvrenKalinbacak/Shutterstock.com

Eurozone

Global

National Security Council's Kirby Notes Early Indications Of Russian Link In Azerbaijan Crash

In a quiet week for economic data, Wall Street&#8217;s focus shifted to the possibility of witnessing a "Santa Rally," the seasonal tendency for stocks to rise in the <a href="https://www.benzinga.com/general/education/24/12/42675763/santa-rally-serial-winners-10-stocks-historically-poised-for-big-year-end-gains">final days of December. </a>
Historically, the S&amp;P 500 has gained 64 times in the past 96 years during the Dec. 24–Dec. 31 window, averaging a 0.85% return.
The market began the week attempting a recover from the Federal Reserve's hawkish signals of fewer rate cuts in 2024. Yet, renewed volatility resurfaced on Friday, casting doubt on the Santa rally's resilience.
Investors remain cautious, as markets weigh Fed policy outlook against uncertainty surrounding the incoming Trump administration's economic plans.
Still, 2024 is shaping up to be a banner year. The S&amp;P 500 is on track to match last year's 24% surge, setting up a two-year gain of 55%, the strongest since 1999. U.S. stocks are also outperforming global markets by the widest margin since 1997, driven by the enduring strength of U.S. economic fundamentals.
On the leaderboards, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) has surged 360%, overtaking Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), last year's top performer, which gained 175% in 2024.
Consumer Confidence Slips
U.S. consumer confidence, as measured by the Conference Board, declined in December, highlighting rising concerns <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42657230/us-consumer-confidence-drops-in-december-expectations-signal-potential-economic-weakness-in-2025">about economic conditions</a>. A deeper drop in the expectations index, a key forward-looking measure, signals potential weakness in 2025 amid fears of persistent inflation and steady, high interest rates.
Tesla's Robotaxi Bet
Elon Musk envisions a Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&#8217;s robotaxi fleet allowing owners to earn $40,000 annually. Despite the bold prediction, experts question the feasibility of the technology and regulatory challenges, suggesting Musk's vision remains aspirational rather than immediately achievable <a href="https://www.benzinga.com/24/12/42642606/elon-musk-wants-to-raise-a-tesla-fleet-expert-estimates-vehicle-owners-can-make-40kyear-but-remains-doubtful">in the near term.</a>
Trump's Tariff Impact
Goldman Sachs projects the Trump administration will raise tariffs on Chinese imports, averaging a 20% hike, with higher rates for non-consumer goods. This could increase consumer prices by 1%-2%, strain industrial margins, disrupt supply chains and <a href="https://www.benzinga.com/government/regulations/24/12/42701155/made-in-china-paid-in-america-what-trumps-new-tariffs-mean-for-the-us-economy">ignite Chinese retaliatory measures,</a> the Wall Street firm says.
Cadillac EV Success
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)&#8217;s Cadillac Lyriq, priced at $60,000, became its best-selling EV in 2024 through the third quarter. The premium EV's success highlights a potential shift toward luxury electric vehicles as automakers target higher <a href="https://www.benzinga.com/tech/24/12/42666472/gms-60000-cadillac-lyriq-was-its-best-selling-ev-in-2024-as-of-q3-is-premium-the-way-to-go-for-ev-makers">margins and affluent buyers.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42710358/veteran-investor-bets-big-on-sp-500-hitting-7000-by-end-of-2025-these-sectors-could-lead-the-charge">Veteran Investor Bets Big On S&amp;P 500 Hitting 7,000 By End Of 2025: These Sectors Could Lead The Charge</a></li>
</ul>
Photo by Marek Maskin on Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Econ #s

Economics

Federal Reserve

NVDA

Wall Street's Santa Rally At Risk, Palantir Dethrones Nvidia, Consumer Confidence Pulls Back: This Week In The Markets

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 30.38% on an annualized basis producing an average annual return of 43.46%. Currently, Vistra has a market capitalization of $47.52 billion. 
Buying $1000 In VST: If an investor had bought $1000 of VST stock 5 years ago, it would be worth $6,120.95 today based on a price of $139.68 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735335008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Vistra 5 Years Ago Would Be Worth This Much Today

VINC

Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.77% on an annualized basis producing an average annual return of 17.46%. Currently, Centene has a market capitalization of $30.59 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 15 years ago, it would be worth $1,117.05 today based on a price of $60.60 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735334113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 15 Years

Management

Vincerx Implements Workforce Reduction Amid Strategic Streamlining; CEO Ahmed Hamdy Steps Down, Raquel Izumi Named Acting CEO, And Kevin Hass Takes Over As Acting CFO As Leadership Transitions Support Ongoing Strategic Efforts

<h3>Gainers</h3>
<ul>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares moved upwards by 38.4% to $3.1 during Friday's pre-market session. The company's market cap stands at $8.7 million. </li>
<li>Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) shares increased by 37.89% to $2.69. The company's market cap stands at $485.0 million. </li>
<li>Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) stock rose 14.96% to $6.3. The market value of their outstanding shares is at $209.7 million. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) stock increased by 13.2% to $0.3. The market value of their outstanding shares is at $4.6 million. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock increased by 13.16% to $0.49. The company's market cap stands at $31.7 million. </li>
<li>Premium Catering (Hldgs) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) stock moved upwards by 12.99% to $0.82. The company's market cap stands at $13.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock declined by 11.6% to $0.46 during Friday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares decreased by 8.14% to $0.34. The company's market cap stands at $1.5 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 6.29% to $1.64. The company's market cap stands at $17.1 million. </li>
<li>JX Luxventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock declined by 5.92% to $0.89. The company's market cap stands at $5.3 million. </li>
<li>Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) shares fell 5.86% to $9.0. The company's market cap stands at $4.2 billion. </li>
<li>Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) stock fell 5.42% to $1.92. The market value of their outstanding shares is at $26.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

AMBO

BRLT

GBTG

LAZR

SLDP

XELB

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

Vincerx Pharma Announces Binding Term Sheet For Strategic Merger With Oqory, Inc.; Oqory Equity Holders To Own 95% Of Combined Entity, Vincerx 5%; Merger Includes $13.66M Equity Value For Vincerx Stockholders And $20M Equity Financing Requirement

<h3>Gainers</h3>
<ul>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock moved upwards by 60.0% to $3.44 during Friday's pre-market session. The market value of their outstanding shares is at $605.0 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares increased by 39.47% to $1.18. The market value of their outstanding shares is at $6.9 million. </li>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock moved upwards by 32.76% to $7.01. The company's market cap stands at $62.3 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock moved upwards by 25.42% to $1.48. The company's market cap stands at $60.0 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares rose 18.01% to $0.99. The market value of their outstanding shares is at $67.9 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 14.35% to $0.8. The market value of their outstanding shares is at $83.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) stock declined by 20.8% to $8.4 during Friday's pre-market session. The market value of their outstanding shares is at $569.8 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares fell 11.83% to $29.0. The company's market cap stands at $157.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock declined by 11.45% to $4.95. The company's market cap stands at $5.5 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) stock declined by 10.38% to $0.21. The market value of their outstanding shares is at $8.4 million. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares decreased by 9.32% to $2.24. The company's market cap stands at $252.7 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock decreased by 8.42% to $0.29. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTCX

DHAI

EVAX

NUTX

PHAR

PROC

PRTG

TLSA

VIRX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares increased by 64.1% to $2.33 during Friday's pre-market session. The market value of their outstanding shares is at $833.2 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares rose 31.69% to $0.55. The company's market cap stands at $67.4 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares increased by 27.9% to $0.61. The company's market cap stands at $17.8 million. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares moved upwards by 23.03% to $2.19. The market value of their outstanding shares is at $14.0 million. </li>
<li>CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) stock rose 22.73% to $1.12. The company's market cap stands at $100.7 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares rose 21.53% to $3.16. The market value of their outstanding shares is at $43.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) shares decreased by 19.0% to $5.02 during Friday's pre-market session. The market value of their outstanding shares is at $102.3 million. </li>
<li>Markforged Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NYSE">MKFG</a>) shares declined by 8.03% to $2.98. The market value of their outstanding shares is at $61.4 million. </li>
<li>Gencor Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GENC#AMEX">GENC</a>) stock declined by 7.4% to $16.85. The company's market cap stands at $247.0 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares declined by 6.95% to $0.43. The market value of their outstanding shares is at $10.8 million. </li>
<li>XCHG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares declined by 6.67% to $2.24. The market value of their outstanding shares is at $133.1 million. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) shares decreased by 6.23% to $0.93. The company's market cap stands at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBAT

GENC

KITT

MKFG

MYNA

NCRA

OMEX

QRHC

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares increased by 359.9% to $2.07 during Friday's pre-market session. The market value of their outstanding shares is at $18.0 million. </li>
<li>My Size (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYSZ#NASDAQ">MYSZ</a>) shares rose 112.08% to $8.95. The market value of their outstanding shares is at $11.2 million. </li>
<li>iLearningEngines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) stock rose 102.6% to $0.33. The market value of their outstanding shares is at $46.1 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares rose 50.0% to $0.81. The market value of their outstanding shares is at $20.4 million. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock moved upwards by 40.62% to $1.8. The market value of their outstanding shares is at $16.4 million. </li>
<li>Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) stock moved upwards by 21.61% to $1.24. The market value of their outstanding shares is at $116.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) stock fell 11.6% to $1.22 during Friday's pre-market session. The market value of their outstanding shares is at $68.4 million. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) stock fell 9.22% to $3.25. The market value of their outstanding shares is at $149.0 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) stock fell 8.34% to $1.54. The market value of their outstanding shares is at $9.4 million. </li>
<li>Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) shares fell 7.69% to $7.57. The company's market cap stands at $215.4 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock fell 5.97% to $2.68. The company's market cap stands at $26.7 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares declined by 5.65% to $0.7. The market value of their outstanding shares is at $17.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AILE

AIRE

IDAI

INTZ

LIDR

MLGO

MYSZ

REKR

SAIH

SGMA

SVCO

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Earnings

CCTG

CCSC Technology International H1 2025 Revenue $9.2M Vs $7.5M YoY; EPS $(0.06) Vs $(0.04) YoY

WIIM

CCSC Technology International Holdings shares are trading higher after the company reported financial results for the first six months of FY25.

Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 20 years by 2.91% on an annualized basis producing an average annual return of 11.28%. Currently, Autodesk has a market capitalization of $63.99 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 20 years ago, it would be worth $7,932.54 today based on a price of $296.92 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735332959_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

Here's How Much $1000 Invested In Autodesk 20 Years Ago Would Be Worth Today

The S&amp;P 500 index is set to end 2024 with its strongest edge over global equities in nearly 30 years, a remarkable streak fueled <a href="https://www.benzinga.com/news/econ-s">by U.S. economic dominance. </a>
Yet, Bank of America analysts caution that the rally's days may be numbered, predicting a reversal as early as the second quarter of 2025.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has surged 25% year-to-date as of Dec. 27, delivering a 21-percentage-point edge over global equities excluding U.S. exposure, tracked by the iShares MSCI ACWI ex U.S. ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACWX#NYSE">ACWX</a>)
That marks the widest outperformance of American versus world equities since 1997. 
This is also the widest performance gap since 1997, driven by investor positioning for &#8220;Trump trades&#8221; of higher U.S. dollar, equities and bond yields, according to Bank of America&#8217;s chief investment strategist Michael Hartnett.
Hartnett predicts that an &#8220;inflation boom&#8221; in the U.S. combined with a &#8220;global deflation bust&#8221; will drive a first-quarter overshoot in U.S. stocks. 
&#8220;We believe US small cap&nbsp;(Russell 2000)&nbsp;is the&nbsp;best trade to&nbsp;position for&nbsp;overshoots,&#8221; Hartnett said in a recent report. 
Hartnett highlighted that global equity markets are heading into 2025 with significantly weak economic momentum, especially in manufacturing &#8211; and this is even before factoring in the potential impact of a trade war.
But, as the champagne flows this New Year's Eve, Bank of America analysis suggests a sobering reality may await from the second quarter of 2025.
<h3 class="wp-block-heading">Chart: S&amp;P 500 Sharply Outperformed International Equities In 2024</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222-1024x557.png" alt="" class="wp-image-709750" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222-1536x835.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27152453/image-222.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">A Shift To International Markets?</h3>
By spring 2025, Bank of America forecasts a hawkish Federal Reserve and &#8220;policy panic&#8221; in Europe and Asia to trigger a peak in U.S. market &#8220;exceptionalism.&#8221; 
According to Hartnett a strong U.S. dollar, already near multi-year highs, contributed to U.S. stocks' outperformance but poses risks given that 30% of S&amp;P 500 revenues come from overseas markets.
Hartnett projects that aggressive fiscal easing in China, new European stimulus – boosted by potential German election outcomes – and rate cuts by the European Central Bank will create fertile ground for global equities.
This could lead to significant rotations into international equities and currencies. 
"By Q2, we anticipate lower interest rates, cheaper currencies, and fiscal easing in Europe and China," Hartnett said.
Emerging markets, battered by a strong dollar and trade uncertainty, may finally rebound as the greenback loses steam.
David Hauner, head of global emerging markets fixed income strategy at Bank Of America, remains cautious on emerging markets in the near term but sees buying opportunities as U.S. trade policies become clearer and the dollar reaches a turning point.
<h3 class="wp-block-heading">2025: Volatility And Opportunity</h3>
Savita Subramanian, Bank of America&#8217;s head of U.S. equity strategy, said potential Trump 2.0 policies could heighten inflation and deficit risks.
&#8220;Trump 2.0 may drive higher uncertainty around inflation and deficit risks.&nbsp;Immigration and tariffs may be inflationary, but corporate tax cuts are disinflationary as benefits get passed onto the consumer,&#8221; Subramanian said.
She highlighted the prospects for a strong GDP upcycle, driven by lighter regulations and increased energy production lowering oil prices.
Despite predictions of volatility return in 2025, Bank of America analysts remain bullish on the S&amp;P 500. 
They indicated an ambitious year-end target of 6,666 for 2025, marking a staggering 10x rally from the market's 2009 lows.
"Volatility will present opportunities to buy the S&amp;P 500 at lower levels in 2025," said Subramanian, adding that the index is likely to close the year higher than current levels.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42701155/made-in-china-paid-in-america-what-trumps-new-tariffs-mean-for-the-us-economy">Made In China, Paid In America: What Trump&#8217;s New Tariffs Mean For The US Economy</a></li>
</ul>
Photo: Shutterstock

Guidance

Analyst Ratings

ACWX

S&P 500 Poised For Best Year Vs. Global Stocks Since 1997: Bank Of America Warns Of 2005 Rotation

GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) are trading higher Friday amid continued interest sparked by reports that the company is evaluating an initial public offering (IPO) for its<a href="https://www.benzinga.com/quote/GDS/news"> data center assets in China.</a>
What To Know: Sources familiar with the matter, who requested anonymity due to the private nature of the discussions, indicated that GDS is collaborating with advisers to gauge investor interest in the potential IPO, <a href="https://www.bloomberg.com/news/articles/2024-12-24/data-center-operator-gds-is-said-to-consider-ipo-of-china-reit">according to Bloomberg.</a> 
The proposed real estate investment trust (REIT) could generate proceeds of approximately 1 billion yuan, equivalent to about $140 million. However, the deliberations are still in preliminary stages and the possibility remains that no final transaction will occur. The company has not provided any official comment on the matter.
Over the past year, the Chinese government has relaxed rules regarding the eligibility of assets for inclusion in REITs, a move that analysts believe could establish China as a significant player in the global commercial property trust market. Since these regulatory changes, 13 REIT IPOs have been priced in China. Furthermore, the China Securities Regulatory Commission is reportedly working on incorporating REITs into the Hong Kong Stock Connect program, a move designed to increase exposure to offshore investors.
The company also announced a $1.2 billion Series B funding round for its international data centers. Notable participants in this round included Coatue Management, SoftBank Vision Fund and Ken Griffin, CEO of Citadel. This funding underscores GDS's broader strategy to position itself as a major player in the global data center space while leveraging favorable developments in the REIT market domestically.
GDS Price Action: GDS Holdings shares were up 7.38% at $22.18 at publication Friday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25-1024x511.png" alt="" class="wp-image-709691" style="width:528px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25-1536x767.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27142803/Screenshot-2024-12-27-at-14.27.25.png 1538w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42709387/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Shutterstock.

REIT

Real Estate

GDS Holdings Shares Are Up Today: What You Need To Know

16:28 EST Ionis Pharmaceuticals (IONS) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...

Ionis Pharmaceuticals trading halted, news pending

Ionis gets FDA approval for Tryngolza

19:00 EST Ionis Pharmaceuticals (IONS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Ionis Pharmaceuticals trading resumes

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration (FDA) has approved Tryngolza as an adjunct to diet to reduce trig...

Ionis Pharmaceuticals reports FDA approval of Tryngolza

H.C. Wainwright analyst Patrick Trucchio believes the FDA approval of Ionis Pharmaceuticals' (IONS) Tryngolza, an oligonucleotide, for the treatmen...

Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) yesterday and set a pri...

Ionis Pharmaceuticals Receives Buy Rating from Jason Gerberry Following FDA Approval of Olezarsen and Promising Market Potential

David Lebowitz, an analyst from Citi, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target is $...

Ionis Pharmaceuticals' Growth Prospects Bolstered by FDA Approval of Tryngolza

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS – Research Report) and...

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report), Ionis ...

Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)

ARWR

SXTP

ZURA

Press Releases

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Ionis to hold third quarter 2024 financial results webcast

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Ionis reports third quarter 2024 financial results

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis to present at upcoming investor conferences

Health Care

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Comments

Ionis Pharmaceuticals

뉴스

에 대한 최신 뉴스 Ionis Pharmaceuticals (NASDAQ:IONS) 주식

금요일, 11월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌